Everence Capital Management’s Quest Diagnostics DGX Stock Holding History

Everence Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.67M	Hold	8,530	–	–	0.1%	170
2025 Q4	$1.48M	Hold	8,530	–	–	0.09%	184
2025 Q3	$1.63M	Hold	8,530	–	–	0.1%	165
2025 Q2	$1.53M	Hold	8,530	–	–	0.1%	173
2025 Q1	$1.44M	Hold	8,530	–	–	0.1%	182
2024 Q4	$1.29M	Sell	8,530 -3,250	-28%	-$505K	0.08%	191
2024 Q3	$1.83M	Hold	11,780	–	–	0.12%	148
2024 Q2	$1.63K	Sell	11,780 -3,080	-21%	-$422K	0.11%	165
2024 Q1	$1.98K	Sell	14,860 -90	-0.6%	-$11.7K	0.13%	147
2023 Q4	$2.06M	Buy	14,950 +11,780	+372%	+$1.55M	0.15%	132
2023 Q3	$386	Buy	+3,170	New	+$422K	0.03%	464
2022 Q1	–	Sell	-2,720	Closed	-$471K	–	745
2021 Q4	$471K	Hold	2,720	–	–	0.04%	446
2021 Q3	$395K	Buy	+2,720	New	+$398K	0.03%	476
2016 Q4	–	Sell	-3,790	Closed	-$321K	–	320
2016 Q3	$321K	Hold	3,790	–	–	0.1%	241
2016 Q2	$309K	Buy	+3,790	New	+$289K	0.09%	237

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Everence Capital Management's DGX Position: Q1 2026 in Review

Everence Capital Management held its Quest Diagnostics (DGX) position steady in Q1 2026 at 8,530 shares worth $1.67M. The position accounts for 0.1% of the portfolio, ranked #170.

Everence Capital Management first reported a position in DGX in Q2 2016 and has held it in 15 quarters since. The position peaked at $2.06M in Q4 2023. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Everence Capital Management held 8,530 shares of Quest Diagnostics worth $1.67M as of Q1 2026.
Everence Capital Management left its Quest Diagnostics share count unchanged in Q1 2026.
Quest Diagnostics made up 0.1% of Everence Capital Management's portfolio in Q1 2026, its #170 holding.
Everence Capital Management first reported a position in Quest Diagnostics in Q2 2016 and has held it in 15 quarters since.
Everence Capital Management's Quest Diagnostics position peaked at $2.06M in Q4 2023.
1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.